Saturday, October 31, 2020
Home Life Style Health & Fitness This Breast Cancer Drug May Help Prostate Cancer Patients

This Breast Cancer Drug May Help Prostate Cancer Patients

The trial studied 387 men with advanced prostate cancer who had defects in one or more of 15 DNA repair genes

A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer, showed results of a major trial which could change clinical practice.

Final results from the trial showed that olaparib — a pioneering type of drug called a PARP inhibitor, a cancer drug to target an inherited genetic fault — can be used successfully to treat prostate cancers with a weakness in their ability to repair damaged DNA.

The drug was more effective than the modern hormone treatments abiraterone and enzalutamide at slowing down the growth and spread of prostate cancer in patients with advanced disease, the results showed.

Follow NewsGram on LinkedIn to know what’s happening around the world.

The trial had already reported an improvement in disease development and outcome for this group of men with DNA repair faults in their tumours — but the final results published at this stage offer a longer follow-up and conclusively demonstrate an improvement in survival for men who were given olaparib.

The trial studied 387 men with advanced prostate cancer who had defects in one or more of 15 DNA repair genes.

Breast cancer drug shows promise to change prostate cancer treatment
The drug was more effective than the modern hormone treatments abiraterone and enzalutamide at slowing down the growth and spread of prostate cancer in patients. Unsplash

Scientists at The Institute of Cancer Research (ICR), London, were the first to discover how olaparib could be targeted at tumours with faults in their ability to repair DNA.

They now expect the concluding results from the trial — presented at the European Society for Medical Oncology on Sunday and published in the journal The New England Journal of Medicine at the same time — to pave the way for regulatory approval of olaparib in prostate cancer in Europe and in the UK.

“I’m confident that our results will transform prostate cancer treatment – hopefully very soon,” said study co-leader Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London.

Want to read more in Hindi? Checkout: किसे अपना कहें और किसे गैरों का समझें? 

“We have shown that olaparib, a drug already approved for use in breast and ovarian cancer, can extend the lives of men with advanced prostate who have defects in the genes BRCA1, BRCA2 or ATM and who have been treated with enzalutamide or abiraterone,”

said de Bono who is also Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.

“The FDA (Food and Drug Administration) has already approved olaparib for prostate cancer in the US and I hope that the final results of our trial will bring the authorisation of this innovative drug to Europe and the UK as soon as possible,” he said.

Men whose tumours had genetic changes were assigned to two groups: one group for those with changes in BRCA1, BRCA2 or ATM, and another group for men with genetic changes in any other of the DNA repair genes studied.

Breast cancer drug shows promise to change prostate cancer treatment
DNA damage is the basic cause of cancer. Unsplash

Men were then randomly assigned to olaparib or standard hormone therapy.

Also Read: Breathing: One of the Most Common Ways by Which Coronavirus is Spread

DNA damage is the basic cause of cancer — but it is also a key weakness of cancer that can be exploited, since cancer cells need to be able to repair their own DNA too.

In the final analysis of data from the “PROfound” trial, researchers found that olaparib blocked prostate cancer growth more effectively than the modern targeted hormone treatments abiraterone and enzalutamide in men with faulty DNA repair genes.

Patients with genetic alterations in the DNA repair genes BRCA1, BRCA2 or ATM who received olaparib had a median overall survival of 19.1 months, compared with 14.7 months for those on targeted hormone treatments, showed the results. (IANS)

STAY CONNECTED

19,120FansLike
362FollowersFollow
1,779FollowersFollow

Most Popular

Menstrual Dysfunction Prevalent in Young Athletes

Researchers, including one of Indian-origin, have found that menstrual dysfunction is more prevalent in young athletes than among non-athletes of a similar age. The study,...

Spinning Keeps You Energized and Your Mind Focused

One of the most popular cardio work-outs in North America, Latin America, Europe, and other parts of Asia, and a current global phenomenon, rhythm-based...

Change in Indian Healthcare Industry is Need of the Hour

With all the chaos created due to the pandemic, a change in the Indian healthcare industry is the need of the hour, feels Anita...

Food Habits to Follow if You Have Arthritis

Arthritis is an autoimmune disease that affects joint and bone pain. It could be a problem or a matter of concern, If not taken...

New Mask Aiming to Make Wearer Less Infectious

People wear face masks to protect others -- not merely to protect themselves. With this in mind, researchers have developed a new concept for...

Cognitive Disorders Increase Risks of Developing Severe COVID

Researchers have claimed that dementia and other cognitive disorders now appear to be the risk factors for developing severe COVID-19. The findings, published in the...

Localized Content Driving New Customers in Amazon Prime Video

Riding on localized content being churned out in countries like India, the number of Prime members who stream Prime Video grew by more than...

Cheerful People Likely to Experience Less Memory Decline

People who feel enthusiastic and cheerful -- what psychologists call "positive affect" -- are less likely to experience memory decline as they age, say...

Recent Comments